Sarcopenia (muscle loss with ageing) adversely affects mobility and stability and increases risk of falls - and mortality- after hip or femur fracture. Developing effective interventions has been a major goal for 30 years but so far only resistance exercise has shown any real benefit. However, this may change with the advent of drug treatments under development, like non-steroidal selective androgen receptor modulators (SARMS) and anti-myostatin antibodies. One promising but different approach has emerged from the increasingly strong evidence that sarcopenia is associated with, and may even be caused by, inflammation of muscle and the blood vessels supplying it.
展开▼
